RENOVORX INC (RNXT) Stock News

USA - NASDAQ:RNXT - US75989R1077 - Common Stock

1.11 USD

+0.1 (+9.36%)

Last: 10/31/2025, 8:12:13 PM

1.1 USD

-0.01 (-0.9%)

Pre-Market: 11/3/2025, 9:05:18 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RNXT Latest News, Press Relases and Analysis

All

Press Releases

25 days ago - By: RenovoRx, Inc.

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

a month ago - By: RenovoRx, Inc.

RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

6 months ago - By: Benzinga

Earnings Preview For RenovoRx

2 months ago - By: ACCESS Newswire - Mentions: NNBR XTRA.CA HIT CJMB ...

Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025

2 months ago - By: RenovoRx, Inc.

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

2 months ago - By: ACCESS Newswire - Mentions: NNBR XTRA.CA HIT OESX ...

iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025

2 months ago - By: Benzinga - Mentions: IFRX ALEC TNYA

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

3 months ago - By: RenovoRx, Inc.

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025

3 months ago - By: The Motley Fool

RenovoRx Revenue Jumps 28 Percent in Q2

3 months ago - By: Zacks Investment Research - Mentions: HQY

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: RenovoRx, Inc.

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

3 months ago - By: RenovoRx, Inc.

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

3 months ago - By: RenovoRx, Inc.

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

4 months ago - By: RenovoRx, Inc.

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

5 months ago - By: Yahoo Finance - Mentions: BBY HSCS KSCP BKNG ...

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

5 months ago - By: Yahoo Finance - Mentions: OMI SMLR RDY HUM ...

Owens & Minor and Rotech Healthcare Agree to End Previously Planned Acquisition

5 months ago - By: Yahoo Finance - Mentions: SO OMI EPD PWR ...

PowerSecure Partners with Edged to Advance Eco-Friendly Data Centers Across the Country

6 months ago - By: Zacks Investment Research - Mentions: AUNA

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: RenovoRx, Inc.

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

6 months ago - By: RenovoRx, Inc.

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

6 months ago - By: RenovoRx, Inc.

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

6 months ago - By: RenovoRx, Inc.

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

6 months ago - By: RenovoRx, Inc.

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

7 months ago - By: RenovoRx, Inc.

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

7 months ago - By: RenovoRx, Inc.

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

7 months ago - By: RenovoRx, Inc.

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial